ABOS NASDAQ Week ended 24 Jul 2026

Weekly Investor Report

Acumen Pharmaceuticals Inc · Healthcare · Biotechnology

Open interactive chart View report data Download investor PDF
Latest close 2.13 USD
-5.3% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -13.9% below the Trend Line and sits at 39.0% of its 52-week range. The latest completed week returned -5.3%, after a -9.7% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is volatility with 52/100 conviction, while the latest news-sentiment score is 55/100. Near-term considerations: volume confirmation is below normal; earnings are due in 13d.

Setup score 25 out of 100
Latest Close 2.13 USD 24 Jul 2026
1W Return -5.3% latest completed week
4W Return -9.7% short-term follow-through
12W Return -10.5% quarterly tape
Trend Breadth 80.8% 42 of 52 weeks active
Volume Ratio 0.5x vs 13-week average
What is working
  • No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is negative, which weakens the current setup.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -5.3% Latest completed week; four-week move -9.7%. Indicator stack 44/45 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 43.87% Historical one-week expectancy contributes to the evidence score when direction is confirmed. Options pressure Volatility 52/100 conviction; expected move 53.1%. News sentiment 55/100 54 relevant articles in the latest sentiment read. Event risk 13d Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -13.9% below the Trend Line and sits at 39.0% of its 52-week range. The latest completed week returned -5.3%, after a -9.7% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.5x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
30 Jan 6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.3212-week average 0.39

12-week confirmation

Trend active5/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership6/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.32Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -9.7% over four weeks, -10.5% over 12 weeks, and 35.7% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W-5.3%
4W-9.7%
12W-10.5%
26W7.6%
52W35.7%
Active trend streak0 weeks
Active weeks in one year42
Trend breadth80.8%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-0.47Latest activity-pressure read.
Pressure change48.9%Four-week change in activity pressure.
Leadership-9.18Latest relative-leadership reading.
RS change-1867.3%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Dec 2025 Field coverage 67% Model confidence 64%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength75/100Blend of value, momentum, and quality. Underlying universe rank 26; rank 1 is best.
Value62/100Relative valuation strength. Underlying universe rank 39; rank 1 is best.
Quality60/100Profitability and accounting quality. Underlying universe rank 41; rank 1 is best.
Momentum62/100Medium-term price momentum. Underlying universe rank 39; rank 1 is best.
Growth62/100Revenue and earnings growth. Underlying universe rank 39; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
-
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-79.2%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-
Gross profit retained from each unit of revenue.
Operating margin
-
Operating profit retained from revenue.
Free-cash-flow margin
-
Free cash flow generated from revenue.
Return on invested capital
-122.3%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
1/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-23.1%
Net share repurchases relative to market value.
Shareholder yield
-23.1%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.2x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningVolatility

ABOS shows volatility options pressure with a 52/100 conviction score, put-call volume ratio of 5.50, expected move of 53.1%, and Sharemaestro trend signal inactive.

Conviction52/100
Expected move53.1%
Put/call volume5.50
Pressure-58
Speculation1
Volatility96
Trend agreement69
Open options detail
Insider activity14 / 6

14 acquisitions and 6 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment55/100

Weighted news tone is neutral across 54 relevant articles.

14 positive · 36 neutral · 4 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings13dNext report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
Options expected move53.1%Nearest-chain priced movement where available.
52-week drawdown-40.8%Distance below the 52-week high.
13-week volatility10.0%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher13 of 2613 weeks finished lower.
Best week+31.3%Week of 30 Jan.
Worst week-18.3%Week of 20 Mar.
Latest week-5.3%Week of 24 Jul.

Shape of recent returns

Strong gains11
Modest gains2
Flat weeks0
Modest losses1
Sharp losses12
Recent vol10.0%13-week weekly-return volatility.
Base vol11.7%52-week weekly-return volatility.
Up/down split26/25Count of positive and negative weeks in the 52-week window.
Average skew10.8% / -8.7%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape28/100

Trend, activity pressure, participation, and risk combine to a 28/100 tape read.

 Indicator analysis34/100

Latest 12-week confirmation: trend 5/12, activity pressure 0/12, relative leadership 6/12.

Activity pressure 0.32; No reversal markers Next-Week ExpectancyNegative 43.87%

Next-week expectancy is negative with a 43.87% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors64/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 92; Small Cap Core rank 46 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options55/100

ABOS shows volatility options pressure with a 52/100 conviction score, put-call volume ratio of 5.50, expected move of 53.1%, and Sharemaestro trend signal inactive.

Volatility · Volatility expansion watch · Expected move 53.1% Sentiment55/100

Weighted news tone is neutral across 54 relevant articles.

Enterprise value to revenue forward of Acumen Pharmaceuticals, Inc. – NASDAQ:ABOS Insiders14 / 6

14 acquisitions and 6 disposals in the latest 180-day insider tape.

 Earnings13d

Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
24 Jul 20262.13 USD-5.3%2.47 USD2.55 USD-0.47-9.181.1MOff
17 Jul 20262.25 USD-14.4%2.47 USD2.59 USD-0.26-5.422.6MOff
10 Jul 20262.63 USD-4.0%2.47 USD2.62 USD-0.396.291.5MOff
3 Jul 20262.74 USD16.1%2.45 USD2.64 USD-0.5913.442.2MOff
26 Jun 20262.36 USD4.4%2.42 USD2.66 USD-0.93-0.477.2MOff
19 Jun 20262.26 USD-4.6%2.41 USD2.68 USD-1.00-8.292.3MOff
12 Jun 20262.37 USD10.2%2.38 USD2.70 USD-0.89-0.821.6MOff
5 Jun 20262.15 USD-17.3%2.36 USD2.72 USD-0.86-7.281.6MOn
29 May 20262.60 USD3.6%2.35 USD2.74 USD-0.767.571.0MOn
22 May 20262.51 USD10.1%2.34 USD2.75 USD-0.787.832.1MOn
15 May 20262.28 USD-10.9%2.33 USD2.77 USD-0.700.021.5MOn
8 May 20262.56 USD7.6%2.32 USD2.79 USD-0.4412.721.3MOn
1 May 20262.38 USD-7.4%2.31 USD2.81 USD-0.2911.621.3MOn
24 Apr 20262.57 USD-8.9%2.29 USD2.83 USD-0.0523.381.7MOn
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.